Belarus and India are working hard to advance cooperation in pharmaceutics, the Chairman of the Council of the Republic of the National Assembly of Belarus Mikhail Myasnikovich reported.
The senator took part in the festivities timed to the opening of a research center of the pharmaceutical company SOOO Nativita in Beshenkovichi, Vitebsk region.
Speaking about the enterprise, Mikhail Myasnikovich mentioned several key aspects.
“It is extremely integrated. Technologies and capital from India, Belarus, Lithuania, and Slovakia are present here. All the best things from several countries are pooled here. It means that the enterprise will be recognizable at least in these countries”, the senator said.
Mikhail Myasnikovich spoke at length about interaction with India since he was in charge of overseeing these matters upon the relevant instruction of the Belarus president.
“We are building three enterprises together with India already. The first one where we are present will be commissioned this year. The foundation of a Belarusian-Indian pharmaceutical enterprise in Kolyadichi has been laid. Experts are evaluating the design specifications and estimates for the Belarusian-Indian enterprise to be located in Skidel, Grodno region. Joint proposals concerning Nesvizh are in the pipeline. We can say that there is serious presence of Indian pharmaceutical products here. India is renowned for its accomplishments in pharmaceutical technologies because the country has been working in this field for a long time. Indian products enjoy popularity and strong demand”, said the head of the upper chamber of the Belarusian parliament.
Speaking about Nativita’s strong points, Mikhail Myasnikovich noted that the enterprise was rather seriously integrated with science.
“A pharmaceutical cluster has been created and operates in Vitebsk region. A technology transfer center was opened in the Vitebsk Medical University a short while ago with assistance of the Council of the Republic. It seems to me that the enterprise has a good future, good prospects ahead of it. We expect that instead of replicating what we can borrow from India or other countries we will be able to research and make new medications of our own”, Myasnikovich stated. The senator went on saying that making proprietary substances was one of the reasons for setting up the enterprise in Beshenkovichi.
The Beshenkovichi enterprise also represents a vivid example of implementing a social and economic development priority – investments in the district capital.
“These are good investments for the sake of developing a science-intensive industry. Pharmaceutics is exactly what the Belarusian economy needs. The ratio of materials and energy is small while the added value is high, primarily thanks to intellectual component”, Mikhail Myasnikovich stated. The new enterprise will make medications using chemical and biological synthesis.
The pharmaceutical company Nativita is a factory specializing in making medications to treat malignant tumors as well as a number of autoimmune and serious infectious diseases. The company’s products have been entered into the national import substitution program. The company was established in 2012. The investors are Natco Pharma Limited (India), OOO VitVar (Vitebsk, Belarus), AO Vita Pharma (Slovakia), and AB ZIA valda (Lithuania). (BelTA/Business World Magazine)